Findings

What do systematic reviews say?

601 questions · 608 findings · 50 reviews · Kidney and Transplant

Sort:Best matchNewest Highest certainty Download CSV

No studies found 127 · 20.9%GRADE not reported 6 · 1%Very low 189 · 31.1%Low 184 · 30.3%Moderate 87 · 14.3%High 15 · 2.5%

Heparin vs placebo

Readmissions to intensive care: all heparin · kidney transplant recipients

It is very uncertain whether heparin changes readmissions to intensive care: all heparin compared with placebo (very low certainty).

1 finding from 1 review

Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes only
RR 0.68 [0.12, 3.9]
3 studies · 180 participants
Very low

Heparin vs placebo

Blood transfusion requirements · kidney transplant recipients

1 finding from 1 review

Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Heparin vs placebo

Graft and patient survival · kidney transplant recipients

1 finding from 1 review

Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Heparin vs placebo

Non‐graft thrombosis · kidney transplant recipients

1 finding from 1 review

Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Eculizumab vs placebo or alternative treatment

Death · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Ravulizumab vs placebo or alternative treatment

Remission · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
56 participants
Very low

Ravulizumab vs placebo or alternative treatment

Change in eGFR · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
56 participants
Very low

Ravulizumab vs placebo or alternative treatment

Health‐related quality of life · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
44 participants
Very low

Ravulizumab vs placebo or alternative treatment

Adverse events · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
58 participants
Very low

Ravulizumab vs placebo or alternative treatment

Meningococcal infection · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
58 participants
Very low

Eculizumab vs placebo or alternative treatment

Requirement for KRT · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Eculizumab vs placebo or alternative treatment

Remission · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Eculizumab vs placebo or alternative treatment

Change in eGFR · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
88 participants
Very low

Eculizumab vs placebo or alternative treatment

Health‐related quality of life · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Eculizumab vs placebo or alternative treatment

Adverse events · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Eculizumab vs placebo or alternative treatment

Meningococcal infection · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Ravulizumab vs placebo or alternative treatment

Death · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
58 participants
Very low

Ravulizumab vs placebo or alternative treatment

Requirement for KRT · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
56 participants
Very low

Bovine colostrum vs placebo

Death (any cause) · patients with diarrhoea due to Shiga toxin‐producing E. coli

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Synsorb Pk vs placebo

Incidence of HUS · patients with diarrhoea due to Shiga toxin‐producing E. coli

It is very uncertain whether synsorb Pk changes incidence of HUS compared with placebo (very low certainty).

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
RR 0.93 [0.39, 2.22]
1 study · 353 participants
Very low